Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026 before market open. The company will host a conference call at 8:30 a.m. Eastern Time the same day.
Dial-in details: 888-455-0391 (U.S./Canada) or 773-756-0467 (international) with passcode 7895081. The earnings release and live webcast will be posted at www.QuestDiagnostics.com/investor. Participants are advised to dial in ~10 minutes early.
A replay will be available online at the investor site and by phone at 866-388-5361 (domestic) or 203-369-0416 (international) from ~10:30 a.m. ET on February 10, 2026 until midnight ET on February 24, 2026. Investors are encouraged to review the company’s periodic SEC filings, including risk factors.
Positive
- None.
Negative
- None.
News Market Reaction – DGX
In the Jan 8 session, DGX declined 0.22%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Clinical data update | Positive | +4.0% | Haystack MRD ctDNA data highlighted at 2026 ASCO GI symposium. |
| Jan 05 | JV partnership | Positive | -0.2% | Corewell Health JV forming Diagnostic Lab of Michigan with Quest majority. |
| Dec 19 | Conference appearance | Neutral | -0.1% | Planned presentation at 44th J.P. Morgan Healthcare Conference. |
| Dec 09 | Research collaboration | Positive | -1.2% | Haystack MRD collaboration in phase II MRD-PORT trial for NSCLC. |
| Dec 01 | Strategic collaboration | Positive | -2.9% | Octave MSDA Test access via ~7,000 Quest patient service centers. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent DGX headlines often read as strategically positive, but price reactions have been mixed, with several constructive collaboration updates followed by modest declines.
Over the past months, Quest Diagnostics issued multiple strategic updates. On Jan 6, 2026, ASCO GI data on the Haystack MRD test coincided with a +4.02% move. A Corewell Health joint venture on Jan 5, 2026 and an Octave MSDA collaboration on Dec 1, 2025 were followed by slight declines. A J.P. Morgan Healthcare Conference appearance on Dec 19, 2025 had minimal price impact. Against this backdrop, today’s earnings-date announcement fits a pattern of operational news with generally moderate stock reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The conference call can be accessed by dialing 888-455-0391 within the
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on February 10, 2026 until midnight Eastern Time on February 24, 2026.
Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-10-2026-302655842.html
SOURCE Quest Diagnostics Incorporated